A new treatment created by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH) is offering promising results for children and adults with T-cell acute lymphoblastic leukemia (T-ALL), a fast-moving and uncommon blood cancer. The approach uses genome-edited immune cells to target the disease in patients who often have very limited treatment options. This first-of-its-kind gene therapy, known as BE-CAR7, relies on base-edited immune cells to attack types of T-cell leukemia that historically could not be treated effectively. Base-editing is an advanced form of CRISPR that changes…
